Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

AIM: To assess the efficacy and safety of fasiglifam 25 and 50 mg in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. METHODS: This phase III, double-blind, placebo-controlled, multicentre study included 192 patients randomized to once-daily treatment with fasigli...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, K, Enya, K, Nakaya, R, Ohira, T, Matsuno, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676912/
https://www.ncbi.nlm.nih.gov/pubmed/25787200
http://dx.doi.org/10.1111/dom.12467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676912/
https://www.ncbi.nlm.nih.gov/pubmed/25787200
http://dx.doi.org/10.1111/dom.12467

Ejemplares similares